Both ACE inhibitors and ARBs are well-recognized for improving prognosis in patients with heart failure and myocardial infarction, demonstrating a beneficial effect in reducing cardiovascular mortality and reversing myocardial remodeling (34–38). This evidence concerns the gene ACE and heart failure.